Table of Contents
International Journal of Proteomics
Volume 2011 (2011), Article ID 343582, 9 pages
http://dx.doi.org/10.1155/2011/343582
Review Article

Protein Biomarkers for the Early Detection of Breast Cancer

1Department of Surgery, University of Michigan Medical School, Ann Arbor, MI 48109-5656, USA
2The Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109-5656, USA

Received 24 May 2011; Accepted 23 June 2011

Academic Editor: Tadashi Kondo

Copyright © 2011 David E. Misek and Evelyn H. Kim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,” The Lancet, vol. 365, pp. 1687–1717, 2005. View at Google Scholar
  3. J. M. Nabholtz, A. Buzdar, M. Pollak et al., “Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial,” Journal of Clinical Oncology, vol. 18, no. 22, pp. 3758–3767, 2000. View at Google Scholar · View at Scopus
  4. J. Bonneterre, B. Thurlimann, J. F. Robertson et al., “Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study,” Journal of Clinical Oncology, vol. 18, no. 22, pp. 3748–3757, 2000. View at Google Scholar · View at Scopus
  5. J. Bonneterre, A. Buzdar, J. M. Nabholtz et al., “Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma,” Cancer, vol. 92, no. 9, pp. 2247–2258, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. C. A. Hudis, “Trastuzumab—Mechanism of action and use in clinical practice,” New England Journal of Medicine, vol. 357, no. 1, pp. 39–51, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. Bilancia, G. Rosati, A. Dinota, D. Germano, R. Romano, and L. Manzione, “Lapatinib in breast cancer,” Annals of Oncology, vol. 18, supplement 6, pp. vi26–vi30, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. G. M. Higa and J. Abraham, “Lapatinib in the treatment of breast cancer,” Expert Review of Anticancer Therapy, vol. 7, no. 9, pp. 1183–1192, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. R. W. Carlson, B. O. Anderson, H. J. Burstein et al., “Invasive breast cancer: clinical practice guidelines in oncology,” Journal of the National Comprehensive Cancer Network, vol. 5, no. 3, pp. 246–312, 2007. View at Google Scholar · View at Scopus
  10. B. J. Yoder, E. J. Wilkinson, and N. A. Massoll, “Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast,” Breast Journal, vol. 13, no. 2, pp. 172–179, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. F. A. Tavassoli, “Invasive lobular carcinoma,” in Pathology of the Breast, F. A. Tavassoli, Ed., pp. 426–36, Appleton & Lange, Stamford, Conn, USA, 2nd edition, 1999. View at Google Scholar
  12. “Invasive lobular carcinoma,” in Rosen’s Breast Pathology, P. P. Rosen, Ed., pp. 627–52, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2nd edition, 2001.
  13. J. S. Reis-Filho, P. T. Simpson, T. Gale, and S. R. Lakhani, “The molecular genetics of breast cancer: the contribution of comparative genomic hybridization,” Pathology Research and Practice, vol. 201, no. 11, pp. 713–725, 2005. View at Publisher · View at Google Scholar · View at PubMed
  14. S. E. Shackney and J. F. Silverman, “Molecular evolutionary patterns in breast cancer,” Advances in Anatomic Pathology, vol. 10, no. 5, pp. 278–290, 2003. View at Google Scholar · View at Scopus
  15. P. T. Simpson, J. S. Reis-Filho, T. Gale, and S. R. Lakhani, “Molecular evolution of breat cancer,” Journal of Pathology, vol. 205, no. 2, pp. 248–254, 2005. View at Publisher · View at Google Scholar · View at PubMed
  16. D. E. Stange, B. Radlwimmer, F. Schubert et al., “High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer,” Clinical Cancer Research, vol. 12, no. 2, pp. 345–352, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. D. G. Albertson, C. Collins, F. McCormick, and J. W. Gray, “Chromosome aberrations in solid tumors,” Nature Genetics, vol. 34, no. 4, pp. 369–376, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. D. G. Albertson and D. Pinkel, “Genomic microarrays in human genetic disease and cancer,” Human Molecular Genetics, vol. 12, no. 2, pp. R145–R152, 2003. View at Google Scholar · View at Scopus
  19. H. Buerger, E. C. Mommers, R. Littmann et al., “Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution,” Journal of Pathology, vol. 194, no. 2, pp. 165–170, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. H. Tsuda and S. Hirohashi, “Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions,” Pathology International, vol. 48, no. 7, pp. 518–525, 1998. View at Google Scholar · View at Scopus
  21. J. E. Somerville, L. A. Clarke, and J. D. Biggart, “c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma,” Journal of Clinical Pathology, vol. 45, no. 1, pp. 16–20, 1992. View at Google Scholar · View at Scopus
  22. A. N. Jain, K. Chin, A. L. Børresen-Dale et al., “Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 14, pp. 7952–7957, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. D. N. Poller, C. E. Hutchings, M. Galea et al., “p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor,” British Journal of Cancer, vol. 66, no. 3, pp. 583–588, 1992. View at Google Scholar · View at Scopus
  24. M. Barbareschi, E. Leonardi, F. A. Mauri, G. Serio, and P. Dalla Palma, “p53 and c-erbB-2 protein expression in breast carcinomas: an immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer,” American Journal of Clinical Pathology, vol. 98, no. 4, pp. 408–418, 1992. View at Google Scholar · View at Scopus
  25. M. Rudas, R. Neumayer, M. F. X. Gnant, M. Mittelböck, R. Jakesz, and A. Reiner, “p53 Protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast,” European Journal of Cancer A, vol. 33, no. 1, pp. 39–44, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. J. E. Eyfjord, S. Thorlacius, M. Steinarsdottir, R. Valgardsdottir, H. M. Ogmundsdottir, and K. Anamthawat-Jonsson, “p53 Abnormalities and genomic instability in primary human breast carcinomas,” Cancer Research, vol. 55, no. 3, pp. 646–651, 1995. View at Google Scholar · View at Scopus
  27. C. Wiltschke, I. Kindas-Muegge, A. Steininger, A. Reiner, G. Reinger, and P. N. Preis, “Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients,” Journal of Cancer Research and Clinical Oncology, vol. 120, no. 12, pp. 737–742, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Seshadri, A. S. Y. Leong, K. Mccaul, F. A. Firgaira, V. Setlur, and D. J. Horsfall, “Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis,” International Journal of Cancer, vol. 69, no. 2, pp. 135–141, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Goldhirsch, M. Colleoni, G. Domenighetti, and R. D. Gelber, “Systemic treatments for women with breast cancer: outcome with relation to screening for the disease,” Annals of Oncology, vol. 14, no. 8, pp. 1212–1214, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Lieberman, “How to screen for colon cancer,” Annual Review of Medicine, vol. 49, pp. 163–172, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. J. A. Ferguson, “Early detection of unsuspected colon cancers in asymptomatic people,” Diseases of the Colon and Rectum, vol. 36, no. 4, p. 411, 1993. View at Google Scholar · View at Scopus
  32. J. S. Mandel, J. H. Bond, T. R. Church et al., “Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study,” New England Journal of Medicine, vol. 328, no. 19, pp. 1365–1371, 1993. View at Publisher · View at Google Scholar · View at PubMed
  33. W. J. Catalona, “Management of cancer of the prostate,” New England Journal of Medicine, vol. 331, no. 15, pp. 996–1004, 1995. View at Publisher · View at Google Scholar · View at PubMed
  34. S. J. Jacobsen, S. K. Katusic, E. J. Bergstralh et al., “Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing,” Journal of the American Medical Association, vol. 274, no. 18, pp. 1445–1449, 1995. View at Google Scholar · View at Scopus
  35. E. Lynge, “Screening for cancer of the cervix uteri,” World Journal of Surgery, vol. 13, no. 1, pp. 71–78, 1989. View at Google Scholar · View at Scopus
  36. F. Le Naour, D. E. Misek, M. C. Krause et al., “Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer,” Clinical Cancer Research, vol. 7, no. 11, pp. 3328–3335, 2001. View at Google Scholar
  37. F. M. Brichory, D. E. Misek, A. M. Yim et al., “An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 17, pp. 9824–9829, 2001. View at Publisher · View at Google Scholar · View at PubMed
  38. A. O. Güre, N. K. Altorki, E. Stockert, M. J. Scanlan, L. J. Old, and Y. T. Chen, “Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3,” Cancer Research, vol. 58, no. 5, pp. 1034–1041, 1998. View at Google Scholar · View at Scopus
  39. E. Stockert, E. Jäger, Y. T. Chen et al., “A survey of the humoral immune response of cancer patients to a panel of human tumor antigens,” Journal of Experimental Medicine, vol. 187, no. 8, pp. 1349–1354, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Ben-Mahrez, I. Sorokine, D. Thierry et al., “Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients,” International Journal of Cancer, vol. 46, no. 1, pp. 35–38, 1990. View at Publisher · View at Google Scholar · View at Scopus
  41. S. M. Pupa, S. Menard, S. Andreola, and M. I. Colnaghi, “Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients,” Cancer Research, vol. 53, no. 24, pp. 5864–5866, 1993. View at Google Scholar · View at Scopus
  42. S. F. Winter, J. D. Minna, B. E. Johnson, T. Takahashi, A. F. Gazdar, and D. P. Carbone, “Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation,” Cancer Research, vol. 52, no. 15, pp. 4168–4174, 1992. View at Google Scholar · View at Scopus
  43. J. Raedle, G. Oremek, M. Welker, W. K. Roth, W. F. Caspary, and S. Zeuzem, “p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma,” Pancreas, vol. 13, no. 3, pp. 241–246, 1996. View at Google Scholar · View at Scopus
  44. P. Lenner, F. Wiklund, S. O. Emdin et al., “Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study,” British Journal of Cancer, vol. 79, no. 5-6, pp. 927–932, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. T. Soussi, “p53 Antibodies in the sera of patients with various types of cancer: a review,” Cancer Research, vol. 60, no. 7, pp. 1777–1788, 2000. View at Google Scholar · View at Scopus
  46. K. Angelopoulou, H. Yu, B. Bharaj, M. Giai, and E. P. Diamandis, “p53 Gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer,” Clinical Biochemistry, vol. 33, no. 1, pp. 53–62, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Kulić, M. Sirotković-Skerlev, S. Jelisavac-Ćosić, D. Herceg, Z. Kovač, and D. Vrbanec, “Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients,” Medical Oncology, vol. 27, no. 3, pp. 887–893, 2010. View at Publisher · View at Google Scholar · View at PubMed
  48. C. Desmetz, F. Bibeau, F. Boissière et al., “Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ,” Journal of Proteome Research, vol. 7, no. 9, pp. 3830–3837, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. C. Desmetz, C. Bascoul-Mollevi, P. Rochaix et al., “Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women,” Clinical Cancer Research, vol. 15, no. 14, pp. 4733–4741, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. S. E. Conroy, S. L. Gibson, G. Brunstrom, D. Isenberg, Y. Luqmani, and D. S. Latchman, “Autoantibodies to 90 kD heat-shock protein in sera of breast cancer patients,” The Lancet, vol. 345, no. 8942, p. 126, 1995. View at Google Scholar · View at Scopus
  51. S. E. Conroy, P. D. Sasieni, I. Fentiman, and D. S. Latchman, “Autoantibodies to the 90 kDa heat shock protein and poor survival in breast cancer patients,” European Journal of Cancer, vol. 34, no. 6, pp. 942–943, 1998. View at Google Scholar · View at Scopus
  52. S. Von Mensdorff-Pouilly, M. M. Gourevitch, P. Kenemans et al., “Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours,” European Journal of Cancer A, vol. 32, no. 8, pp. 1325–1331, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Von Mensdorff-Pouilly, A. A. Verstraeten, P. Kenemans et al., “Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin,” Journal of Clinical Oncology, vol. 18, no. 3, pp. 574–583, 2000. View at Google Scholar · View at Scopus
  54. O. Blixt, D. Bueti, B. Burford et al., “Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis,” Breast Cancer Research, vol. 13, no. 2, article R25, 2011. View at Publisher · View at Google Scholar · View at PubMed
  55. M. J. Duffy, “CA 15-3 and related mucins as circulating markers in breast cancer,” Annals of Clinical Biochemistry, vol. 36, no. 5, pp. 579–586, 1999. View at Google Scholar · View at Scopus
  56. M. J. Duffy, D. Evoy, and E. W. McDermott, “CA 15-3: uses and limitation as a biomarker for breast cancer,” Clinica Chimica Acta, vol. 411, no. 23-24, pp. 1869–1874, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. B. De La Lande, K. Hacene, J. L. Floiras, N. Alatrakchi, and M. F. Pichon, “Prognostic value of CA 15.3 kinetics for metastatic breast cancer,” International Journal of Biological Markers, vol. 17, no. 4, pp. 231–238, 2002. View at Google Scholar · View at Scopus
  58. F. G. Ebeling, P. Stieber, M. Untch et al., “Serum CEA and CA 15-3 as prognostic factors in primary breast cancer,” British Journal of Cancer, vol. 86, no. 8, pp. 1217–1222, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. M. Gion, P. Boracchi, R. Dittadi et al., “Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game,” European Journal of Cancer, vol. 38, no. 9, pp. 1181–1188, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. E. J. Kumpulainen, R. J. Keskikuru, and R. T. Johansson, “Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer,” Breast Cancer Research and Treatment, vol. 76, no. 2, pp. 95–102, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Martín, M. D. Corte, A. M. Álvarez et al., “Prognostic value of pre-operative serum CA 15.3 levels in breast cancer,” Anticancer Research, vol. 26, no. 5B, pp. 3965–3971, 2006. View at Google Scholar · View at Scopus
  62. R. Molina, X. Filella, J. Alicarte et al., “Prospective evaluation of CEA and CA 15.3 in Patients with locoregional breast cancer,” Anticancer Research, vol. 23, no. 2A, pp. 1035–1041, 2003. View at Google Scholar · View at Scopus
  63. J. Madoz-Gúrpide, H. Wang, D. E. Misek, F. Brichory, and S. M. Hanash, “Protein based microarrays: a tool for probing the proteome of cancer cells and tissues,” Proteomics, vol. 1, no. 10, pp. 1279–1287, 2001. View at Google Scholar · View at Scopus
  64. M. J. Nam, J. Madoz-Gurpide, H. Wang et al., “Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3,” Proteomics, vol. 3, no. 11, pp. 2108–2115, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. K. Bouwman, J. Qiu, H. Zhou et al., “Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity,” Proteomics, vol. 3, no. 11, pp. 2200–2207, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. J. Qiu, J. Madoz-Gurpide, D. E. Misek et al., “Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens,” Journal of Proteome Research, vol. 3, no. 2, pp. 261–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. N. Ramachandran, E. Hainsworth, B. Bhullar et al., “Self-assembling protein microarrays,” Science, vol. 305, no. 5680, pp. 86–90, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. N. Ramachandran, J. V. Raphael, E. Hainsworth et al., “Next-generation high-density self-assembling functional protein arrays,” Nature Methods, vol. 5, no. 6, pp. 535–538, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. K. S. Anderson, S. Sibani, G. Wallstrom et al., “Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer,” Journal of Proteome Research, vol. 10, no. 1, pp. 85–96, 2011. View at Publisher · View at Google Scholar · View at PubMed
  70. C. L. Hattrup and S. J. Gendler, “Structure and function of the cell surface (tethered) mucins,” Annual Review of Physiology, vol. 70, pp. 431–457, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. D. W. Kufe, “Mucins in cancer: function, prognosis and therapy,” Nature Reviews Cancer, vol. 9, no. 12, pp. 874–885, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. R. Molina, J. M. Augé, J. M. Escudero et al., “Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value,” Tumor Biology, vol. 31, no. 3, pp. 171–180, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. Y. Fan, J. Wang, Y. Yang et al., “Detection and identification of potential biomarkers of breast cancer,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 8, pp. 1243–1254, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. M. C. Gast, E. J. van Dulken, T. K. van Loenen et al., “Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling,” International Journal of Biological Markers, vol. 24, no. 3, pp. 130–141, 2009. View at Google Scholar · View at Scopus
  75. M. C. Gast, C. H. van Gils, L. F. Wessels et al., “Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS,” Oncology Reports, vol. 22, no. 1, pp. 205–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Lebrecht, D. Boehm, M. Schmidt, H. Koelbl, and F. H. Grus, “Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry to detect breast cancer markers in tears and serum,” Cancer Genomics and Proteomics, vol. 6, no. 2, pp. 75–84, 2009. View at Google Scholar · View at Scopus
  77. A. W. Van Winden, M. C. W. Gast, J. H. Beijnen et al., “Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study,” BMC Medical Genomics, vol. 2, article 4, 2009. View at Publisher · View at Google Scholar · View at PubMed
  78. C. Belluco, E. F. Petricoin, E. Mammano et al., “Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer,” Annals of Surgical Oncology, vol. 14, no. 9, pp. 2470–2476, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. G. Ricolleau, C. Charbonnel, L. Lodé et al., “Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors,” Proteomics, vol. 6, no. 6, pp. 1963–1975, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. C. Laronga, S. Becker, P. Watson et al., “SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers,” Disease Markers, vol. 19, no. 4-5, pp. 229–238, 2003. View at Google Scholar · View at Scopus
  81. J. Li, Z. Zhang, J. Rosenzweig, Y. Y. Wang, and D. W. Chan, “Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer,” Clinical Chemistry, vol. 48, no. 8, pp. 1296–1304, 2002. View at Google Scholar · View at Scopus
  82. E. R. Sauter, W. Davis, W. Qin et al., “Identification of a β-casein-like peptide in breast nipple aspirate fluid that is associated with breast cancer,” Biomarkers in Medicine, vol. 3, no. 5, pp. 577–588, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. J. Zhou, B. Trock, T. N. Tsangaris et al., “A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient,” Breast Cancer Research and Treatment, vol. 123, no. 1, pp. 73–86, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. J. L. Noble, R. S. Dua, G. R. Coulton, C. M. Isacke, and G. P. H. Gui, “A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer,” European Journal of Cancer, vol. 43, no. 16, pp. 2315–2320, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. J. He, J. Gornbein, D. Shen et al., “Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry,” International Journal of Oncology, vol. 30, no. 1, pp. 145–154, 2007. View at Google Scholar · View at Scopus
  86. J. Li, J. Zhao, X. Yu et al., “Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid,” Clinical Cancer Research, vol. 11, no. 23, pp. 8312–8320, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. T. M. Pawlik, H. Fritsche, K. R. Coombes et al., “Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry,” Breast Cancer Research and Treatment, vol. 89, no. 2, pp. 149–157, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. E. R. Sauter, S. Shan, J. E. Hewett, P. Speckman, and G. C. Du Bois, “Proteomic analysis of nipple aspirate fluid using SELDl-TOF-MS,” International Journal of Cancer, vol. 114, no. 5, pp. 791–796, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. C. P. Paweletz, B. Trock, M. Pennanen et al., “Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer,” Disease Markers, vol. 17, no. 4, pp. 301–307, 2001. View at Google Scholar · View at Scopus
  90. T. M. Pawlik, D. H. Hawke, Y. Liu et al., “Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein,” BMC Cancer, vol. 6, article no. 68, 2006. View at Publisher · View at Google Scholar · View at PubMed
  91. P. M. Rudd, T. Elliott, P. Cresswell, I. A. Wilson, and R. A. Dwek, “Glycosylation and the immune system,” Science, vol. 291, no. 5512, pp. 2370–2376, 2001. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Kobata and J. Amano, “Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours,” Immunology and Cell Biology, vol. 83, no. 4, pp. 429–439, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. D. H. Dube and C. R. Bertozzi, “Glycans in cancer and inflammation—Potential for therapeutics and diagnostics,” Nature Reviews Drug Discovery, vol. 4, no. 6, pp. 477–488, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. T. F. Ørntoft and E. M. Vestergaard, “Clinical aspects of altered glycosylation of glycoproteins in cancer,” Electrophoresis, vol. 20, no. 2, pp. 362–371, 1999. View at Google Scholar · View at Scopus
  95. O. J. Semmes, G. Malik, and M. Ward, “Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer,” Journal of Cellular Biochemistry, vol. 98, no. 3, pp. 496–503, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. N. K. Wong, R. L. Easton, M. Panico et al., “Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125,” Journal of Biological Chemistry, vol. 278, no. 31, pp. 28619–28634, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. S. Prakash and P. W. Robbins, “Glycotyping of prostate specific antigen,” Glycobiology, vol. 10, no. 2, pp. 173–176, 2000. View at Google Scholar · View at Scopus
  98. T. M. Block, M. A. Comunale, M. Lowman et al., “Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 779–784, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. R. Peracaula, G. Tabarés, L. Royle et al., “Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins,” Glycobiology, vol. 13, no. 6, pp. 457–470, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. D. F. Hayes, M. Abe, J. Siddiqui, C. Tondini, and D. W. Kufe, “Clinical and molecular investigations of the DF3 breast cancer-associated antigen,” in Immunological Approaches to the Diagnosis and Therapy of Breast Cancer II, R. L. Ceriani, Ed., pp. 45–53, Plenum, New York, NY, USA, 1989. View at Google Scholar
  101. S. R. Hull, A. Bright, K. L. Carraway, M. Abe, D. F. Hayes, and D. W. Kufe, “Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line,” Cancer Communications, vol. 1, no. 4, pp. 261–267, 1989. View at Google Scholar · View at Scopus
  102. L. Perey, D. F. Hayes, and D. Kufe, “Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope,” Cancer Research, vol. 52, no. 22, pp. 6365–6370, 1992. View at Google Scholar · View at Scopus
  103. L. Perey, D. F. Hayes, P. Maimonis, M. Abe, C. O'Hara, and D. W. Kufe, “Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen,” Cancer Research, vol. 52, no. 9, pp. 2563–2568, 1992. View at Google Scholar · View at Scopus
  104. R. Sewell, M. Bäckström, M. Dalziel et al., “The ST6GalNAc-I sialyltransferase localizes throughout the golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer,” Journal of Biological Chemistry, vol. 281, no. 6, pp. 3586–3594, 2006. View at Publisher · View at Google Scholar · View at PubMed
  105. J. M. Burchell, A. Mungul, and J. Taylor-Papadimitriou, “O-linked glycosylation in the mammary gland: changes that occur during malignancy,” Journal of Mammary Gland Biology and Neoplasia, vol. 6, no. 3, pp. 355–364, 2001. View at Publisher · View at Google Scholar · View at Scopus
  106. M. T. Goodarzi and G. A. Turner, “Decreased branching, increased fucosylation and changed sialylation of alpha-1-proteinase inhibitor in breast and ovarian cancer,” Clinica Chimica Acta, vol. 236, no. 2, pp. 161–171, 1995. View at Publisher · View at Google Scholar · View at Scopus
  107. J. W. Dennis and S. Laferte, “Oncodevelopmental expression of -GlcNAcβ1-6Manα1-6Manβ1- branched asparagine-linked oligosaccharides in murine tissues and human breast carcinomas,” Cancer Research, vol. 49, no. 4, pp. 945–950, 1989. View at Google Scholar · View at Scopus
  108. B. Fernandes, U. Sagman, M. Auger, M. Demetrio, and J. W. Dennis, “β1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia,” Cancer Research, vol. 51, no. 2, pp. 718–723, 1991. View at Google Scholar · View at Scopus
  109. K. L. Abbott, K. Aoki, J. M. Lim et al., “Targeted glycoproteomic identification of biomarkers for human breast carcinoma,” Journal of Proteome Research, vol. 7, no. 4, pp. 1470–1480, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. U. M. Abd Hamid, L. Royle, R. Saldova et al., “A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression,” Glycobiology, vol. 18, no. 12, pp. 1105–1118, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. Z. Kyselova, Y. Mechref, P. Kang et al., “Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles,” Clinical Chemistry, vol. 54, no. 7, pp. 1166–1175, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. W. R. Alley, M. Madera, Y. Mechref, and M. V. Novotny, “Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery,” Analytical Chemistry, vol. 82, no. 12, pp. 5095–5106, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus